

Prof Laure Gossec
Professor Laure Gossec is Professor of Rheumatology in Sorbonne Université and Pitié-Salpêtrière Hospital, Paris, France. Professor Gossec has a half-time clinical position where she mainly sees patients with inflammatory arthritis, and a half-time teaching and research position.
Professor Gossec earned her medical degree and conducted her specialty training in rheumatology at Paris Descartes University, France, and earned her PhD in clinical epidemiology from Montpellier University, France. Professor Gossec’s clinical research focuses on particular outcomes research and epidemiological research, with a focus on outcome measures, prediction of outcome and targeted treatments, in psoriatic arthritis (PsA), rheumatoid arthritis (RA) and spondyloarthritis. Professor Gossec is particularly interested in the patient’s perspective and patient-centred research, and e-health and artificial intelligence for rheumatology research.
In 2023, Professor Gossec has coordinated work on quality of life in spondyloarthritis in several databases, she was the methodologist for a European Alliance of Associations of Rheumatology (EULAR) Task Force on patient involvement in research (led by Dr de Wit, Netherlands) and she co-led a EULAR Task Force with Professor Smolen (Austria) to produce an update of the EULAR recommendations for the management of PsA.
Professor Gossec is past Chair of the Epidemiology standing committee of EULAR and is a founding member and past Chair of the Emerging EULAR Network (EMEUNET). She is an Associate Editor for Joint Bone Spine.
Professor Gossec has authored more than 450 peer-reviewed manuscripts published in journals such as Annals of the Rheumatic Diseases, Arthritis & Rheumatology, Rheumatology and Arthritis Research and Therapy.
Prof. Christos Zouboulis and Dr Axel Villani kick-off the webinar series by explaining the fundamentals of the HS disease story and pathophysiology
Accompany Dr William Tillett and Dr Fabian Proft as they explore the approaches and challenges of managing D2T patients with PsA.
Achieving MDA or DAPSA treatment targets improves quality of life for patients with PsA.1–4 Explore the characteristics of patients who report treatment success...
ASDAS and BASDAI are commonly used in clinical practice.1,2 However, discover recent studies demonstrating that a high proportion of real-world patients do not...
Explore which treatment targets may be more appropriate for making treatment decisions in axSpA.
PsA and axSpA have overlapping disease manifestations which are driven by inflammation.1 Explore several extracellular cytokines that are implicated in these...